WaveMan
WaveMan · Company
RLMD · Relmada Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RLMD Relmada Therapeutics (RLMD) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001553643
Quote by TradingView
C-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
83
13F, latest reported quarter

What the filings say about RLMD

Insiders, 180 days
+$1.7M net bought
2 buyers

Relmada Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, RELMADA THERAPEUTICS, INC. insiders bought a net $1.7M of stock across 52 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Shenouda Maged
Chief Financial Officer
BUY
2026-09-11 SECtraded 2026-09-10
79,800
$339.1K
-27.3%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Sep 9, 2026.
  • -5.1% median (-9.8% mean) 90-day return after 11 previous buys.
  • The trade is 8.0% of the 1,000,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Shenouda Maged bought about $339.1K of RLMD on Sep 10, 2026; 1 other insider bought within 30 days and 83 funds added in the latest 13F quarter.
TRAVERSA SERGIO
Chief Executive Officer
BUY
2026-09-11 SECtraded 2026-09-10
100,000
$410.0K
-27.3%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (16 buys, 5 sales), the last on Sep 9, 2026.
  • +30.5% median (+98.1% mean) 90-day return after 15 previous buys.
  • The trade is 6.7% of the 1,500,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer TRAVERSA SERGIO bought about $410.0K of RLMD on Sep 10, 2026; 1 other insider bought within 30 days and 83 funds added in the latest 13F quarter.
Shenouda Maged
Chief Financial Officer
BUY
2026-09-11 SECtraded 2026-09-09
120,200
$504.8K
-27.3%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on Dec 15, 2025.
  • -5.1% median (-9.8% mean) 90-day return after 11 previous buys.
  • The trade is 13.1% of the 920,200 shares held after it.
  • 1 other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Shenouda Maged bought about $504.8K of RLMD on Sep 9, 2026; 1 other insider bought within 30 days and 83 funds added in the latest 13F quarter.
TRAVERSA SERGIO
Chief Executive Officer
BUY
2026-09-11 SECtraded 2026-09-09
100,000
$418.0K
-27.3%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (15 buys, 5 sales), the last on Dec 15, 2025.
  • +30.5% median (+98.1% mean) 90-day return after 15 previous buys.
  • The trade is 7.1% of the 1,400,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer TRAVERSA SERGIO bought about $418.0K of RLMD on Sep 9, 2026; 1 other insider bought within 30 days and 83 funds added in the latest 13F quarter.
TRAVERSA SERGIO
Chief Executive Officer
BUY
2025-12-16 SECtraded 2025-12-15
27,500
$113.3K
-19.5%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (14 buys, 5 sales), the last on Nov 5, 2025.
  • +20.8% median (+102.1% mean) 90-day return after 14 previous buys.
  • The trade is 2.1% of the 1,300,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer TRAVERSA SERGIO bought about $113.3K of RLMD on Dec 15, 2025; 1 other insider bought within 30 days and 83 funds added in the latest 13F quarter.
52 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 47 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.7M over 180 days
+$1.7M over 90 days
more than 91% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
83 funds bought in last quarter
more than 61% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
$9.8M repurchased, FY to 2026-06-30
below 72% of Pharma & Biotech
Short interest
14.7% of the float short (float per yahoo 2026-10-27) · 8.5 days to cover · settled 2026-10-15
more than 76% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch RLMD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+46.2%12M
-5%+82%+169%+256%2025-102025-122026-022026-042026-062026-082026-10 2025-11-05 · Shenouda Maged bought $1.1M2025-11-05 · TRAVERSA SERGIO bought $599.5K2026-09-09 · Shenouda Maged bought $504.8K2026-09-09 · TRAVERSA SERGIO bought $418.0K2026-09-10 · TRAVERSA SERGIO bought $410.0K2026-09-10 · Shenouda Maged bought $339.1K2025-11-05 · Ence Chuck bought $299.2K2025-11-05 · Kelly Paul Edward bought $198.0K2025-12-15 · TRAVERSA SERGIO bought $113.3K2025-12-15 · Shenouda Maged bought $48.1K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RLMD: institutional holders (13F)

13F holdings, latest reported quarter
Jupiter Topco LLC
11,164,803 sh
$77.3M
BlackRock, Inc.
7,426,780 sh
$51.4M
Squadron Capital Management LLC
7,350,000 sh
$50.9M
Venrock Adviser, LLC
6,844,305 sh
$47.4M
Spruce Street Capital LP
6,391,328 sh
$44.2M

Congress trades in RLMD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RLMD planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

RLMD mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$3.0M position · as of 2026-06-30
6.8%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$4.5M position · as of 2026-06-30
1.1%
PROFUND VP PHARMACEUTICALS
$118.2K position · as of 2026-06-30
1.0%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$125.0K position · as of 2026-07-31
0.6%
Virtus Biotech Clinical Trials Etf
$248.2K position · as of 2026-07-31
0.5%
Eventide Healthcare & Life Sciences Fund
$7.0M position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
1 active
6
Phase 3
1 active
1
Not applicable
0 active
What changed recently
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-mus
2026-09-03 · Completion moved 2029-09 → 2029-12
Phase 3
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
2026-09-03 · Completion moved 2025-08 → 2027-11
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.7M bought by insiders over 180 days, 83 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RLMD financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$46.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-4.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-3.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-57.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-13.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$59.1M-$83.9M-$103.7M-$161.2M
Net income$0$0$0-$157.0M
EPS (diluted)n/an/an/a-5.30
Operating cash flow-$45.8M-$51.8M-$51.7M-$103.8M
Cash$3.5M$3.9M$4.1M$5.4M
SEC XBRL, fiscal years, as known on 2026-10-28

RLMD Stock Sonar score 4/7 axes

Find similar shapesCompare

RLMD ranks highest on insider conviction (86th percentile) and profitability (68th), and lowest on risk and compliance (25th), among Pharma & Biotech peers.

Profitability
68
Inputs
  • Return on equity-4.1% · 80 pct, sector of 545
  • Return on assets-3.8% · 79 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-57.2% · 43 pct, sector of 576
Insider conviction
86
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.7M · 91 pct, sector of 429
  • Insider buyers, 180d2 · 81 pct, sector of 438
Institutional and government
61
Inputs
  • Funds adding, latest quarter83 · 61 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
25
Inputs
  • Short interest, % of float+14.7% · 25 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RLMD filings, in plain words

Are Relmada Therapeutics insiders buying or selling RLMD?

In the 180 days to 2026-10-28, Relmada Therapeutics insiders were net buyers, a net $1.7M across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Relmada Therapeutics insiders were net buyers of RLMD, a net $1.7M across purchases and sales reported on Form 4 by 2 buyers. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies